High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2013-01, Vol.15 (1), p.104-111
• Main Authors: Patil, Chirag G, Nuño, Miriam, Elramsisy, Adam, Mukherjee, Debraj, Carico, Christine, Dantis, Jocelynn, Hu, Jethro, Yu, John S, Fan, Xuemo, Black, Keith L, Bannykh, Serguei I
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms - drug therapy; Brain Neoplasms - metabolism; Brain Neoplasms - mortality; Clinical Investigations; Dacarbazine - analogs & derivatives; Dacarbazine - therapeutic use; Female; Follow-Up Studies; Gene Amplification; Glioblastoma - drug therapy; Glioblastoma - metabolism; Glioblastoma - mortality; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mitogen-Activated Protein Kinases - metabolism; Phosphorylation; Prognosis; PTEN Phosphohydrolase - metabolism; Receptor, Epidermal Growth Factor - genetics; Retrospective Studies; Survival Rate; Young Adult
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nos272

We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era. Nuclear p-MAPK expression of 108 patients with GBM was quantified and categorized in the following levels: low (0%-10%), medium (11%-40%), and high (41%-100%). Independent predictors of overall survival were determined using a multivariate Cox proportional hazards model. Our study included 108 patients with newly diagnosed GBM. Median age was 65 years, and 74% had high Karnofsky performance status (KPS ≥ 80). Median overall survival among all patients was 19.5 months. Activated MAPK expression levels of